Genuine Biotech Wins First Prize of Henan Provincial Patent Award

Recently, the People's Government of Henan Province issued the Resolution on the Governor's Award of Quality (Patent) of Henan Province (Yu Zheng [2026] No. 9), and Genuine Biotech Co., Ltd. won the first prize of the Henan Provincial Patent Award for the patent "Use of Nucleoside Compounds in the Preparation of Drugs for the Treatment of Coronavirus Infectious Diseases".

The Henan Provincial Patent Award is the highest commendation for intellectual property innovation in the province. It is selected once every two years, and this is the fifth award cycle. Winning this award is a high recognition of the innovation capability of Genuine Biotech.

Azvudine, the core achievement of the award-winning patent, is a Class 1.1 innovative drug independently developed by Genuine Biotech. In Jul. 2022, Azvudine was conditionally approved by the National Medical Products Administration (NMPA) for the treatment of common COVID-19 in adults, making it the first oral antiviral drug developed by a Chinese company and approved by the NMPA for the treatment of COVID-19.

In the HIV therapeutic area, in Jul. 2021, Azvudine was conditionally approved by the NMPA for the treatment of HIV-1 infected adults with high viral load. As a novel dual-target nucleoside antiviral drug, Azvudine can inhibit both reverse transcriptase and accessory protein Vif, and has been included in the "Chinese Guidelines for Diagnosis and Treatment of Human Immunodeficiency Virus Infection/Acquired Immunodeficiency Syndrome" (2021 and 2024 Editions).

In Apr. 2023, Azvudine was included in the "National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog", and its safety and efficacy were supported by real-world data and 177 papers published by independent third parties. At present, Azvudine has sold more than 10 million vials, covering more than 50,000 medical terminals in 31 provinces and cities across China, effectively ensuring public access to the medication.

At present, the company is developing Azvudine for the treatment of immune non-responder (INR) HIV patients. The company has jointly applied with Peking Union Medical College Hospital, Chinese Academy of Medical Sciences to include the development of this indication as a National Science and Technology Major Project in 2025, and the application has been approved by the Ministry of Science and Technology of China.

In the anti-tumor field, Azvudine has a dual anti-tumor mechanism, i.e., it can not only inhibit the DNA synthesis in tumor cells, but also improve the immunity through immune regulation, playing a further anti-tumor role. On this basis, the phase II clinical trial of Azvudine monotherapy for the treatment of hematological tumors was granted IND approval by the NMPA in Dec. 2025.

Furthermore, Genuine Biotech has established an Azvudine+ drug development platform centered on its core product Azvudine, aiming to further exploit the clinical and commercial potentials of Azvudine and actively explore the potential of Azvudine in combination with tumor immunotherapy drugs, targeted therapy drugs, and chemotherapy drugs.

Among them, Genuine Biotech, in cooperation with Innovent Biologics, was granted IND approval of the combination therapy of "Azvudine + Sintilimab (a PD-1 inhibitor)" for the treatment of liver cancer and colorectal cancer by the NMPA in Feb. 2026; was granted IND approval of the combination therapy of Azvudine + Dosimertinib for the treatment of non-small cell lung cancer by the NMPA in Sep. 2025.

In addition, based on the long-acting effects of Azvudine and CL-197 confirmed by preclinical studies, the company also plans to develop an all-oral long-acting combination tablet that can achieve combination effects on the three targets. As a candidate drug for the treatment of HIV infection that is taken once a week, the combination tablet is expected to improve medication compliance and thus improve clinical outcomes.

Winning the first prize of the Henan Provincial Patent Award demonstrates the profound accumulation of Genuine Biotech in the field of innovative drug research and development. In the future, the company will remain innovation-driven to address unmet clinical needs, accelerate the clinical progress and commercialization of its anti-viral and anti-tumor pipelines, and provide safer and more effective treatment options for patients worldwide.